<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001761</url>
  </required_header>
  <id_info>
    <org_study_id>980059</org_study_id>
    <secondary_id>98-I-0059</secondary_id>
    <nct_id>NCT00001761</nct_id>
  </id_info>
  <brief_title>Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis</brief_title>
  <official_title>Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerance, and immunologic effects of&#xD;
      interleukin-10 (IL-10), in patients with Wegener's granulomatosis. A secondary objective is&#xD;
      to determine if IL-10 demonstrates sufficient anti-inflammatory activity in the treatment of&#xD;
      Wegener's granulomatosis to warrant further study in a larger trial. In this study, IL-10&#xD;
      will be given either alone or in combination with standard therapeutic agents, usually&#xD;
      consisting of cyclophosphamide, methotrexate, and/or prednisone. Patients will be eligible to&#xD;
      receive IL-10 when there is evidence of active disease. IL-10 will be administered by&#xD;
      subcutaneous injection at a dose of 4 µ (Micro)g/kg/day for 28 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to assess the safety, tolerance, and immunologic effects of&#xD;
      interleukin-10 (IL-10), in patients with Wegener's granulomatosis. A secondary objective is&#xD;
      to determine if IL-10 demonstrates sufficient anti-inflammatory activity in the treatment of&#xD;
      Wegener's granulomatosis to warrant further study in a larger trial. In this study, IL-10&#xD;
      will be given either alone or in combination with standard therapeutic agents, usually&#xD;
      consisting of cyclophosphamide, methotrexate, and/or prednisone. Patients will be eligible to&#xD;
      receive IL-10 when there is evidence of active disease. IL-10 will be administered by&#xD;
      subcutaneous injection at a dose of 4 µ (Micro)g/kg/day for 28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1998</start_date>
  <completion_date>April 2000</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>15</enrollment>
  <condition>Vasculitis</condition>
  <condition>Wegener's Granulomatosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-10</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Diagnosis of Wegener's granulomatosis based on clinical characteristics and&#xD;
        histopathological and/or angiographic evidence of vasculitis or the presence of&#xD;
        glomerulonephritis and a positive assay for anti-neutrophil cytoplasmic autoantibodies&#xD;
        (ANCA).&#xD;
&#xD;
        Age between 18 to 65 years.&#xD;
&#xD;
        No change in immunosuppressive drug therapy during the prior 4 weeks and one of the&#xD;
        following:&#xD;
&#xD;
        Persistent disease activity (&quot;Vasculitis Activity Index&quot; score of greater than or equal to&#xD;
        3) despite optimal therapy;&#xD;
&#xD;
        Persistent or recurrent disease activity in a patient who cannot tolerate optimal therapy;&#xD;
&#xD;
        Patients not on maximal immunosuppressive therapy but with persistent or recurrent disease&#xD;
        activity that is not, in the judgment of investigators, immediately threatening the&#xD;
        function of a major organ system;&#xD;
&#xD;
        No evidence of active infection.&#xD;
&#xD;
        Patients may not be pregnant or nursing infants. Fertile women must have a negative&#xD;
        pregnancy test within one week prior to study entry and all participants must be using&#xD;
        effective means of birth control.&#xD;
&#xD;
        Serum creatinine is less than 3.5 mg/dL.&#xD;
&#xD;
        Hemocytopenia (platelet count is greater than 100,000/mm(3), leukocyte count is greater&#xD;
        than 3,500/mm(s), hemoglobin is greater than 9 mg/dL).&#xD;
&#xD;
        Liver function test abnormalities is less than 3x upper limits of normal (either serum GOT,&#xD;
        GPT, alkaline phosphatase, and/or bilirubin).&#xD;
&#xD;
        Patients cannot be anti-HIV, anti-HCV, or anti-Hepatitis B surface antigen (HBsAG)&#xD;
        positive.&#xD;
&#xD;
        Weight greater less than 104 Kg (because of SCH 52000 concentration and volume limitations&#xD;
        for subcutaneous injection).&#xD;
&#xD;
        No treatment with any investigational drug within 30 days.&#xD;
&#xD;
        No pre-existing malignancy.&#xD;
&#xD;
        No known allergy to E. coli protein or IL-10.&#xD;
&#xD;
        No history of psychiatric illness that in the opinion of the principal investigator would&#xD;
        preclude entrance into the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institute of Allergy and Infectious Diseases (NIAID)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992 Mar 15;116(6):488-98. doi: 10.7326/0003-4819-116-6-488.</citation>
    <PMID>1739240</PMID>
  </reference>
  <reference>
    <citation>Ludviksson BR, Sneller MC, Chua KS, Talar-Williams C, Langford CA, Ehrhardt RO, Fauci AS, Strober W. Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol. 1998 Apr 1;160(7):3602-9.</citation>
    <PMID>9531324</PMID>
  </reference>
  <verification_date>January 1999</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>December 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2002</study_first_posted>
  <last_update_submitted>March 3, 2008</last_update_submitted>
  <last_update_submitted_qc>March 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <keyword>Autoimmunity</keyword>
  <keyword>Cytokine</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Interleukin</keyword>
  <keyword>Vasculitis</keyword>
  <keyword>Wegener's Granulomatosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Vasculitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

